Andrea Sgoifo
University of Parma, Italy
Biography
<p style="margin:0in;margin-bottom:.0001pt;text-align:justify">
<span style="font-family:times new roman,times,serif;"><b>Biography: </b>Born in Udine (Italy), on August the 3rd 1962.</span><o:p></o:p></p>
<p style="margin: 0in 0in 0.0001pt;">
<span style="font-family:times new roman,times,serif;">MS in Biological Sciences (Univ. of Parma, Italy, 1987). </span><o:p></o:p></p>
<p style="margin: 0in 0in 0.0001pt;">
<span style="font-family:times new roman,times,serif;">PhD in Cardiovascular Pathophysiology (Univ. of Milano, 1994). </span><o:p></o:p></p>
<p style="margin: 0in 0in 0.0001pt;">
<span style="font-family:times new roman,times,serif;">Post-doc grant on Stress Physiology (Univ. of Groningen, NL, 1996-98). Assistant professor, Univ. of Parma (1998-2005).</span><o:p></o:p></p>
<p style="margin: 0in 0in 0.0001pt;">
<span style="font-family:times new roman,times,serif;">Associate Professor of Physiology, Dept. of Chemistry, Life Sciences & Environmental Sustainability, Univ. of Parma (since 2005). </span><o:p></o:p></p>
<p style="margin: 0in 0in 0.0001pt;">
<span style="font-family:times new roman,times,serif;">Full professorship qualification received from the Italian Ministry of University & Research, January 2014.</span><o:p></o:p></p>
<p style="margin: 0in 0in 0.0001pt;">
<span style="font-family:times new roman,times,serif;">Director of the Stress Physiology Lab, University of Parma (since 2005)</span><o:p></o:p></p>
<p style="margin: 0in 0in 0.0001pt;">
<span style="font-family:times new roman,times,serif;">Director of the Stress Control Lab, Italian College of Osteopathy (since 2016).</span></p>
<p>
<span style="font-family:times new roman,times,serif;"><strong>Research Interesrt(s): </strong>Research activity focuses on the biological substrates of depression/anxiety and autonomic/cardiovascular dysfunction comorbidity. This topic is approached via preclinical research on animal models of depression (based on adverse social conditions) and anxiety (based on lines selectively bred). Proendocannabinoid pharmacological treatment (FAAH inhibition) is tested to verify its pevention/reversal potential over behavioral and physiological symptoms of anxiety/depression as well as over autonomic/cardiovascular dysfunction. Part of the research activity is also devoted to the evaluation of a number of chronic stress parameters in various human populations.</span></p>